Literature DB >> 7380461

Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.

D C Henderson, D Parker, J L Turk.   

Abstract

A comparison was made in mice between resistance to growth of a syngeneic methylcholanthrene-induced fibrosarcoma (Meth A) and specific delayed-type hypersensitivity to this tumour. Resistance could be induced in 90% of mice following a single injection of 10(4) Meth A cells. This resistance could be transferred by spleen cells but not serum. Delayed skin reactivity to ultrasonicated Meth A cells was found in both tumour-resistant and tumour-bearing mice and could be passively transferred by spleen cells and serum. These findings suggest a dissociation between tumour resistance and specific delayed-type hypersensitivity. It would appear that, in this system, delayed skin reactivity to Meth A tumour cells is mediated by humoral antibody despite a mononuclear cell infiltrate at 24 and 48 h and that this could be the reason for its lack of correlation with host resistance to tumour growth which is cell-mediated and not transferable by serum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7380461      PMCID: PMC1457770     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  Influence of cyclophosphamide on the delayed hypersensitivity of the mouse.

Authors:  J A Kerckhaert; G J Van den Berg; J M Willers
Journal:  Ann Immunol (Paris)       Date:  1974 Mar-Apr

2.  Impaired inflammatory response in tumor-bearing guinea pigs.

Authors:  I D Bernstein; B Zbar; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1972-12       Impact factor: 13.506

3.  Contact sensitivity in the mouse. V. The role of macrophage cytophilic antibody in passive transfer and the effect of trypsin and anti-gamma globulin serum.

Authors:  M Zembala; G L Asherson
Journal:  Cell Immunol       Date:  1970-09       Impact factor: 4.868

4.  Delayed cutaneous hypersensitivity reactions to extracts of human tumors.

Authors:  R B Herberman; A C Hollinshead; T C Alford; J L McCoy; R H Halterman; B G Leventhal
Journal:  Natl Cancer Inst Monogr       Date:  1973-06

5.  Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; D Parker; L W Poulter
Journal:  Immunology       Date:  1972-10       Impact factor: 7.397

6.  Cutaneous delayed hypersensitivity responses to tumor-associated and other antigens in acute leukemia.

Authors:  D H Char; B G Lepourhiet; R B Herberman
Journal:  Int J Cancer       Date:  1973-09-15       Impact factor: 7.396

7.  A study of the passive cellular transfer of local cutaneous hypersensitivity. IV. Transfer of hypersensitivity to sheep erythroytes with peritoneal exudate cells passively coated with antibody.

Authors:  L Hulliger; A A Blazkovec; E Sorkin
Journal:  Int Arch Allergy Appl Immunol       Date:  1968

8.  Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells.

Authors:  M E Oren; R B Herberman
Journal:  Clin Exp Immunol       Date:  1971-07       Impact factor: 4.330

9.  Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response?

Authors:  M W Johnson; H I Maibach; S E Salmon
Journal:  N Engl J Med       Date:  1971-06-03       Impact factor: 91.245

Review 10.  Immune deficiency states associated with malignant disease in man.

Authors:  J Harris; R C Bagai
Journal:  Med Clin North Am       Date:  1972-03       Impact factor: 5.456

View more
  2 in total

1.  Activation of lamina propria T cells induces crypt epithelial proliferation and goblet cell depletion in cultured human fetal colon.

Authors:  C M Evans; A D Phillips; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

2.  Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.